Provided by Tiger Fintech (Singapore) Pte. Ltd.

INNOVENT BIO

50.250
+0.4000.80%
Volume:24.88M
Turnover:1.23B
Market Cap:82.31B
PE:-811.07
High:51.000
Open:49.200
Low:47.750
Close:49.850
Loading ...

Innovent Biologics - Q3 Total Product Revenue Exceeded RMB2.3 Bln

THOMSON REUTERS
·
30 Oct 2024

Innovent Biologics, Inc.'s (HKG:1801) recent 15% pullback adds to one-year year losses, institutional owners may take drastic measures

Simply Wall St.
·
29 Oct 2024

Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-Il-23P19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients With Prior Inadequate Response to Il-17 Biologics

THOMSON REUTERS
·
29 Oct 2024

Stock Track | Innovent Bio Plunges Over 13% on Dilution of Stake in Unit

Stock Track
·
28 Oct 2024

Innovent Biologics Unit to Issue, Sell Over 12.8 Million Shares

MT Newswires Live
·
28 Oct 2024

Innovent Biologics - Lostrancos Ventures to Subscribe for 12.8 Mln New Series Pre-a Preferred Shares for $20.5 Mln

THOMSON REUTERS
·
25 Oct 2024

Innovent Biologics - Deemed Disposal of Equity Interest in Unit

THOMSON REUTERS
·
25 Oct 2024

Innovent Announces Phase 2 Clinical Study of Picankibart (Ibi112) in Chinese Patients With Ulcerative Colitis Met Primary Endpoint

THOMSON REUTERS
·
17 Oct 2024

Hong Kong Stocks Fall on Uncertainty in Further Stimulus; Pharma Firms Lead Decline

MT Newswires Live
·
14 Oct 2024

BRIEF-Innovent And Ask Pharm Announce Strategic Collaboration For Limertinib, A Third-Generation Egfr Tki For The Treatment Of Lung Cancer

Reuters
·
08 Oct 2024

Innovent Biologics Inc - Obtains Exclusive Commercialization Rights for Limertinib in Mainland China

THOMSON REUTERS
·
08 Oct 2024

Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-Generation Egfr Tki for the Treatment of Lung Cancer

THOMSON REUTERS
·
08 Oct 2024

Don't Ignore The Insider Selling In Innovent Biologics

Simply Wall St.
·
06 Oct 2024